Category: Markets
Published: 2026-06-22T22:19:42.000Z
Taysha Gene Therapies, Inc.'s average stock price target has increased from $12.23 to $12.31, based on estimates from 13 analysts, with a range of $8 to $19 per share. This updated target indicates a potential upside of approximately 92% from its June 18 closing price. All 13 covering analysts maintain a "Buy" rating for the stock.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.